sucroferric oxyhydroxide


Fresenius Kabi


Concise Prescribing Info
Sucroferric oxyhydroxide
Control of serum P levels in adult chronic kidney disease patients on haemodialysis or peritoneal dialysis.
Dosage/Direction for Use
1,500 mg Fe (3 tab) per day, divided across the meals of the day. Titrate up or down in increments of 500 mg Fe (1 tab) per day every 2-4 wk until an acceptable serum P level is reached. Max: 3,000 mg Fe (6 tab) per day.
Should be taken with food: Tab must be chewed & not swallowed whole. Tab may be crushed.
Hypersensitivity. Haemochromatosis & any other Fe accumulation disorders.
Special Precautions
Patients w/ recent history of peritonitis (w/in the last 3 mth), significant gastric or hepatic disorders & patients w/ major GI surgery. Contains sucrose & starch. Caution in patients w/ rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency; DM. Can cause discoloured (black) stool. Pregnancy & lactation. Childn <18 yr.
Adverse Reactions
Diarrhoea, faeces discoloured. Nausea, constipation, vomiting, dyspepsia, abdominal pain, flatulence, tooth discolouration; product taste abnormal.
Drug Interactions
For concomitant treatment w/ medicinal products w/ a narrow therapeutic window, monitor clinical effect & adverse events on initiation or dose-adjustment of either Velphoro or the concomitant medicinal product. When administering any medicinal product that is already known to interact w/ Fe (eg, alendronate & doxycycline) or has the potential to interact w/ Velphoro (eg, levothyroxine), the medicinal product should be administered at least 1 hr before or 2 hr after Velphoro.
ATC Classification
V03AE05 - sucroferric oxyhydroxide ; Belongs to the class of drugs used in the treatment of hyperkalemia and hyperphosphatemia.
Velphoro chewable tab 500 mg
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in